Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A parenteral pharmaceutical formulation comprising a therapeutically effective amount of a pharmaceutically acceptable base addition salt of a boronic acid of formula (I):



(I)

wherein

Y comprises a hydrophobic moiety which, together with the aminoboronic acid residue $-NHCH(R^9)-B(OH)_2$, has affinity for the substrate binding site of thrombin; and

R^9 is a straight chain alkyl group interrupted by one or more ether linkages and in which the total number of oxygen and carbon atoms is 3, 4, 5 or 6 or R^9 is $-(CH_2)_m-W$ where m is from 2, 3, 4 or 5 and W is –OH or halogen.

Claim 2 (original): The formulation of claim 1 wherein R^9 is an alkoxyalkyl group.

Claim 3 (original): The formulation of claim 1 wherein YCO- comprises an amino acid residue which binds to the S2 subsite of thrombin, the amino acid residue being N-terminally linked to a moiety which binds the S3 subsite of thrombin.

Claim 4 (original): The formulation of claim 1 wherein Y comprises a dipeptide which binds to the S3 and S2 binding sites of thrombin.

Claim 5 (original): The formulation of claim 4 wherein the S3-binding amino acid residue is of (R)-configuration, the S2-binding residue is of (S)-configuration, and the fragment –NHCH(R^9)-B(OH) is of (R)-configuration.

Claim 6 (previously presented): The formulation of claim 5 wherein R^9 is an alkoxyalkyl group.

Claim 7 (original): The formulation of claim 1 wherein the boronic acid has a Ki for thrombin of about 100 nM or less.

Claim 8 (original): The formulation of claim 1 wherein the salt comprises a salt of the boronic acid with metal or a strongly basic organic nitrogen-containing compound.

Claim 9 (original): The formulation of claim 1 wherein the salt comprises a salt of the boronic acid with an alkali metal, an aminosugar, a guanidine or an amine of formula (XI):



(XI)

where n is from 1 to 6, R^2 is H, carboxylate or derivatised carboxylate, R^3 is H, C_1-C_4 alkyl or a residue of a natural or unnatural amino acid.

Claim 10 (original): The formulation of claim 4 wherein the Y dipeptide is N-terminally protected or N-terminally unprotected, and the peptide linkages in the dipeptide are unsubstituted or independently N-substituted by a C_1-C_{13} hydrocarbyl, wherein the C_1-C_{13} hydrocarbyl contains no heteratoms or at least one in-chain or in-ring nitrogen, oxygen or sulfur atom, and the C_1-C_{13} hydrocarbyl is unsubstituted or substituted by a substituent selected from halo, hydroxy and trifluoromethyl.

Claim 11 (original): The formulation of claim 1 wherein the salt consists essentially of an acid salt in which one B-OH group of formula (I), when trigonally represented, remains protonated.

Claim 12 (original): The formulation of claim 9 wherein the salt comprises boronate ions derived from the peptide boronic acid and has a stoichiometry consistent with the boronate ions carrying a single negative charge.

Claim 13 (original): The formulation of claim 6 wherein the salt consists essentially of a monosodium or monolithium salt of the boronic acid.

Claim 14 (original): The pharmaceutical formulation of claim 9 which is adapted for intravenous administration.

Claim 15 (original): A formulation in parenteral dosage form comprising a therapeutically effective amount of a pharmaceutically acceptable base addition salt of a boronic acid of formula (II):



(II)

where:

X is H or an amino-protecting group;

aa^1 is an amino acid residue having a hydrocarbyl side chain containing no more than 20 carbon atoms and comprising at least one cyclic group having up to 13 carbon atoms;

aa^2 is an imino acid residue having from 4 to 6 ring members;

R^1 is a group of the formula $-(CH_2)_s-Z$, where s is 2, 3 or 4 and Z is –OH, –OMe, –OEt or halogen.

Claim 16 (previously presented): The formulation of claim 15 wherein aa^1 is selected from Phe, Dpa or wholly or partially hydrogenated analogues thereof.

Claim 17 (original): The formulation of claim 16 wherein aa^1 is of R-configuration.

Claim 18 (original): The formulation of claim 15 wherein aa^2 is a residue of an imino acid of formula (IV)



(IV),

where R^{11} is $-CH_2-$, $-CH_2-CH_2-$, $-S-CH_2-$, $-S-C(CH_3)_2-$ or $-CH_2-CH_2-CH_2-$, and, when the formula (IV) ring is 5- or 6- membered, the formula (IV) ring is unsubstituted or is substituted at one or more $-CH_2-$ groups by from 1 to 3 C_1-C_3 alkyl groups.

Claim 19 (original): The formulation of claim 18 wherein aa^2 is of S-configuration.

Claim 20 (original): The formulation of claim 15, wherein aa^1-aa^2 is (R)-Phe-(S)-Pro and the fragment $-NH-CH(R^1)-B(OH)_2$ is of R-configuration.

Claim 21 (original): The formulation of claim 16 wherein the boronic acid is of formula (VIII):

X-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$(VIII),

wherein X is R^6-$(CH_2)_p$-C(O)-, R^6-$(CH_2)_p$-$S(O)_2$-, R^6-$(CH_2)_p$-NH-C(O)- or R^6-$(CH_2)_p$-O-C(O)- wherein p is 0, 1, 2, 3, 4, 5 or 6 and R^6 is H or a 5 to 13-membered cyclic group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen; amino; nitro; hydroxy; a C_5-C_6 cyclic group; C_1-C_4 alkyl and C_1-C_4 alkyl containing, or linked to the cyclic group through, an in-chain O atom, the aforesaid alkyl groups optionally being substituted by a substituent selected from halogen, amino, nitro, hydroxy and a C_5-C_6 cyclic group.

Claim 22 (original): The formulation of claim 16 wherein the salt comprises a salt of the boronic acid with an alkali metal, an aminosugar or an amine of formula (XI):



(XI)

where n is from 1 to 6, R^2 is H, carboxylate or derivatised carboxylate, R^3 is H, C_1-C_4 alkyl or a residue of a natural or unnatural amino acid.

Claim 23 (original): A pharmaceutical product comprising a sealed container containing in the form of a finely divided solid, ready for reconstitution to form a liquid parenteral formulation, a therapeutically effective amount of a boronate salt which consists essentially of a single pharmaceutically acceptable base addition salt of a boronic acid formula (II):



(II)

where:

X is H or an amino-protecting group;

aa^1 is an amino acid residue of R-configuration having a hydrocarbyl side chain containing no more than 20 carbon atoms and comprising at least one cyclic group having up to 13 carbon atoms;

aa^2 is an imino acid residue of S-configuration having from 4 to 6 ring members;

C* is a chiral centre of R-configuration; and

R^1 is a group of the formula $-(CH_2)_s-Z$, where s is 2, 3 or 4 and Z is –OH, –OMe, –OEt or halogen.

Claim 24 (currently amended): A pharmaceutical formulation adapted for parenteral administration, whether directly or after combining with a liquid, and comprising

a) a first species selected from a boronic acid of formula (I), ~~and~~ or said boronic acid when in the form of boronate ions of said boronic acid, ~~and~~ or equilibrium forms of said boronic acid and said boronate ions, or combinations thereof:



(I)

wherein

Y comprises a hydrophobic moiety which, together with the aminoboronic acid residue $-NHCH(R^9)-B(OH)_2$, has affinity for the substrate binding site of thrombin; and

R^9 is a straight chain alkyl group interrupted by one or more ether linkages and in which the total number of oxygen and carbon atoms is 3, 4, 5 or 6 or R^9 is $-(CH_2)_m$-W where m is from 2, 3, 4 or 5 and W is –OH or halogen; and

(b) a second, pharmaceutically acceptable, species selected from ~~pharmaceutically acceptable~~ metal ions~~, said metal ions having a valency of n, lysine, arginine or aminosugars~~ and basic organic nitrogen containing compounds having a pKb of about 7 or more,

~~wherein the formulation has an observed stoichiometry of first to second species essentially consistent with a notional stoichiometry of 1:1 when the second species is a metal ion with a valency of 1 or is lysine, arginine or an aminosugar, or an observed stoichiometry of n:1 when the second species is a metal ion with a valency of greater than 1~~.

Claim 25 (original): A method of inhibiting thrombin in the prophylaxis or therapy of disease, comprising parenterally administering to a mammal suffering from, or at risk of suffering from, thrombosis a therapeutically effective amount of the salt defined in claim 1.

Claim 26 (original): A method for preventing thrombosis in a haemodialysis circuit of a patient, for preventing a cardiovascular event in a patient with end stage renal disease, for preventing venous thromboembolic events in a patient receiving chemotherapy through an indwelling catheter, for preventing thromboembolic events in a patient undergoing a lower limb arterial reconstructive procedure, or for treating by way of therapy or prophylaxis an arterial disease selected from acute coronary syndromes, cerebrovascular thrombosis, peripheral arterial occlusion and arterial thrombosis resulting from atrial fibrillation, valvular heart disease, arterio-venous shunts, indwelling catheters or coronary stents, the method comprising parenterally administering to a mammal a therapeutically effective amount of the salt defined in claim 16.

Claim 27 (currently amended): A method for making a salt of claim 1, comprising:

combining in a solvent diethanolamine and an ester of a boronic acid as defined in claim 1;

allowing or causing a precipitate to form and recovering the precipitate;

converting the precipitated material into the free organoboronic acid by contacting the precipitated material with an aqueous acid or base; and

reacting the organoboronic acid with a base of a pharmaceutically acceptable ~~multivalent metal~~ base to form to a salt as defined in claim 1.

Claim 28 (original): A medicament adapted for parenteral administration and comprising a therapeutically effective amount of a pharmaceutically acceptable base addition salt of a boronic acid which is a selective thrombin inhibitor and has a neutral aminoboronic acid residue capable of binding to the thrombin S1 subsite linked through a peptide linkage to a hydrophobic moiety capable of binding to the thrombin S2 and S3 subsites, the salt comprising a cation having a valency n and having an observed stoichiometry consistent with a notional stoichiometry (boronic acid:cation) of n:1.

Claim 29 (original): A medicament of claim 28 wherein the boronic acid has a Ki for thrombin of about 100 nM or less.

Claim 30 (previously presented): The method of claim 25, wherein the boronic acid is of formula (VIII):

X-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$(VIII),

wherein X is R^6-$(CH_2)_p$-C(O)-, R^6-$(CH_2)_p$-$S(O)_2$-, R^6-$(CH_2)_p$-NH-C(O)- or R^6-$(CH_2)_p$-O-C(O)- wherein p is 0, 1, 2, 3, 4, 5 or 6 and R^6 is H or a 5 to 13-membered cyclic group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen; amino; nitro; hydroxy; a C_5-C_6 cyclic group; C_1-C_4 alkyl and C_1-C_4 alkyl containing, or linked to the cyclic group through, an in-chain O atom, the aforesaid alkyl groups optionally being substituted by a substituent selected from halogen, amino, nitro, hydroxy and a C_5-C_6 cyclic group.

Claim 31 (previously presented): The method of claim 30, wherein X is R^6-$(CH_2)_p$-O-C(O)-.

Claim 32 (previously presented): The method of claim 31, wherein R^6 is a 6-membered cyclic group that is unsubstituted and p is 1.

Claim 33 (previously presented): The method of claim 25, wherein the salt is an alkali metal salt.

Claim 34 (previously presented): The method of claim 33, wherein the alkali metal salt is a sodium salt.

Claim 35 (previously presented): The method of claim 26, wherein the boronic acid is of formula (VIII):

X-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$(VIII),

wherein X is R^6-$(CH_2)_p$-C(O)-, R^6-$(CH_2)_p$-$S(O)_2$-, R^6-$(CH_2)_p$-NH-C(O)- or R^6-$(CH_2)_p$-O-C(O)- wherein p is 0, 1, 2, 3, 4, 5 or 6 and R^6 is H or a 5 to 13-membered cyclic group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen; amino; nitro; hydroxy; a C_5-C_6 cyclic group; C_1-C_4 alkyl and C_1-C_4 alkyl containing, or linked to the cyclic group through, an in-chain O atom, the aforesaid alkyl groups optionally being substituted by a substituent selected from halogen, amino, nitro, hydroxy and a C_5-C_6 cyclic group.

Claim 36 (previously presented): The method of claim 35, wherein X is R^6-$(CH_2)_p$-O-C(O)-.

Claim 37 (previously presented): The method of claim 36, wherein R^6 is benzyloxycarbonyl.

Claim 38 (previously presented): The method of claim 26, wherein the salt is an alkali metal salt.

Claim 39 (previously presented): The method of claim 38, wherein the alkali metal salt is a sodium salt.

Claim 40 (previously presented): The formulation of claim 21, wherein X is R^6-$(CH_2)_p$-O-C(O)-.

Claim 41 (previously presented): The formulation of claim 40, wherein R^6 is benzyloxycarbonyl.

Claim 42 (previously presented): The formulation of claim 21, wherein the formulation is an aqueous solution comprising the salt.

Claim 43 (previously presented): The formulation of claim 42, wherein the aqueous solution further comprises a tonicity agent.

Claim 44 (previously presented): The formulation of claim 42, wherein the salt is an alkali metal salt.

Claim 45 (previously presented): The formulation of claim 44, wherein the alkali metal salt is a sodium salt.

Claim 46 (previously presented): The formulation of claim 1, wherein the formulation comprises an aqueous solution of the salt.

Claim 47 (previously presented): A method of inhibiting thrombin in the prophylaxis or therapy of disease, comprising parenterally administering to a mammal suffering from, or at risk of suffering from, thrombosis, the formulation of claim 1.

Claim 48 (previously presented): The method of claim 47, wherein the boronic acid is of formula (VIII):

X-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$(VIII),

wherein X is R^6-$(CH_2)_p$-C(O)-, R^6-$(CH_2)_p$-$S(O)_2$-, R^6-$(CH_2)_p$-NH-C(O)- or R^6-$(CH_2)_p$-O-C(O)- wherein p is 0, 1, 2, 3, 4, 5 or 6 and R^6 is H or a 5 to 13-membered cyclic group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen; amino; nitro; hydroxy; a C_5-C_6 cyclic group; C_1-C_4 alkyl and C_1-C_4 alkyl containing, or linked to the cyclic group through, an in-chain O atom, the aforesaid alkyl groups optionally being substituted by a substituent selected from halogen, amino, nitro, hydroxy and a C_5-C_6 cyclic group.

Claim 49 (previously presented): The method of claim 48, wherein the formulation is an aqueous solution comprising the salt.

Claim 50 (previously presented): The method of claim 49, wherein the formulation is administered intravenously.

Claim 51 (currently amended): A method for preventing thrombosis in a haemodialysis circuit of a patient, for preventing a cardiovascular event in a patient with end stage renal disease, for preventing venous thromboembolic events in a patient receiving chemotherapy through an indwelling catheter, for preventing thromboembolic events in a patient undergoing a lower limb arterial reconstructive procedure, or for treating by way of therapy or prophylaxis an arterial disease selected from acute coronary syndromes, cerebrovascular thrombosis, peripheral arterial occlusion and arterial thrombosis resulting from atrial fibrillation, valvular heart disease, arterio-venous shunts, indwelling catheters or coronary stents, the method comprising parenterally administering to a mammal the formulation of claim ~~16~~ 17.

Claim 52 (previously presented): The method of claim 51, wherein the boronic acid is of formula (VIII):

X-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$(VIII),

wherein X is R^6-$(CH_2)_p$-C(O)-, R^6-$(CH_2)_p$-$S(O)_2$-, R^6-$(CH_2)_p$-NH-C(O)- or R^6-$(CH_2)_p$-O-C(O)- wherein p is 0, 1, 2, 3, 4, 5 or 6 and R^6 is H or a 5 to 13-membered cyclic group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen; amino; nitro; hydroxy; a C_5-C_6 cyclic group; C_1-C_4 alkyl and C_1-C_4 alkyl containing, or linked to the cyclic group through, an in-chain O atom, the aforesaid alkyl groups optionally being substituted by a substituent selected from halogen, amino, nitro, hydroxy and a C_5-C_6 cyclic group.

Claim 53 (previously presented): The method of claim 52, wherein the formulation is an aqueous solution comprising the salt.

Claim 54 (previously presented): The method of claim 53, wherein the formulation is administered intravenously.

Claim 55 (currently amended): The method of claim 25, further comprising co-administering ~~a~~ at least one further cardiovascular treatment agent.

Claim 56 (currently amended): The method of claim 26, further comprising co-administering ~~a~~ at least one further cardiovascular treatment agent.

Claim 57 (previously presented): A method of inhibiting thrombin in the prophylaxis or therapy of disease, comprising parenterally administering to a mammal suffering from, or at risk of suffering from, thrombosis a therapeutically effective amount of the pharmaceutical formulation of claim 24.

Claim 58 (new): The formulation of claim 1 which comprises anhydride species of the acid.

Claim 59 (new): The formulation of claim 15 which comprises the boronic acid in the form of an anhydride.

Claim 60 (new): The formulation of claim 1 wherein the salt is a metal salt of the boronic acid.

Claim 61 (new): The formulation of claim 58 wherein the salt is a metal salt of the boronic acid.

Claim 62 (new): The formulation of claim 59 wherein the salt is a metal salt of the boronic acid.

Claim 63 (new): The formulation of claim 23 wherein the boronic acid is of the formula Cbz-(R)-Phe-(S)-Pro-(R)-boroMpg-OH, boroMpg-OH being a residue of an aminoboronic acid of the formula H_2N-CH($(CH_2)_3$OMe)B$(OH)_2$, and wherein the formulation comprises anhydride species of the acid.

Claim 64 (new): The formulation of claim 63 wherein the salt is an alkali or alkaline earth metal salt of the boronic acid.

Claim 65 (new): The formulation of claim 63 wherein the salt is a monosodium salt of the boronic acid.

Claim 66 (new): The formulation of claim 63wherein the salt is a hemicalcium salt of the boronic acid.

Claim 67 (new): The formulation of claim 4 wherein R^9 is 3-methoxypropyl and the carbon atom to which R^9 is bonded comprises a chiral centre of (R)-configuration.

Claim 68 (new): The formulation of claim 67 wherein the salt consists essentially of an alkali metal or alkaline earth metal salt.

Claim 69 (new): The formulation of claim 67 wherein the salt consists essentially of a sodium salt.

Claim 70 (new): The formulation of claim 67 wherein the salt consists essentially of a monosodium salt.

Claim 71 (new): The formulation of claim 67 wherein the salt consists essentially of a salt of the boronic acid with an aminosugar, a guanidine or an amine of formula (XI):



(XI)

where n is from 1 to 6, R^2 is H, carboxylate or derivatised carboxylate, R^3 is H, C_1-C_4 alkyl or a residue of a natural or unnatural amino acid.

Claim 72 (new): The formulation of claim 67 which comprises an aqueous solution containing the salt.

Claim 73 (new): The formulation of claim 67 which comprises the boronic acid in the form of an anhydride.

Claim 74 (new): The formulation of claim 67 which is adapted for intravenous formulation and is either in the form of an aqueous solution or is in solid form for making up into an aqueous solution for administration.

Claim 75 (new): The formulation of claim 74 wherein the boronic acid is of the formula Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$.

Claim 76 (new): The formulation of claim 75 wherein the salt is an alkali metal salt.

Claim 77 (new): The formulation of claim 75 wherein the salt is a sodium salt.

Claim 78 (new): The formulation of claim 75 wherein the salt is a monosodium salt.

Claim 79 (new): The formulation of claim 75 wherein the salt is a hemicalcium salt.

Claim 80 (new): The formulation of claim 75 wherein the salt is a hemimagnesium salt.

Claim 81 (new): The formulation of claim 1 wherein the boronic acid is of the formula Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$.

Claim 82 (new): The formulation of claim 1 wherein the salt is a metal salt of a boronic acid of the formula Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$.

Claim 83 (new): The formulation of claim 1 wherein the salt is an alkali metal or alkaline earth metal salt of a boronic acid of the formula Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$.

Claim 84 (new): The formulation of claim 1 wherein the salt consists essentially of a monosodium salt of a boronic acid of the formula Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$.

Claim 85 (new): The formulation of claim 84 which comprises anhydride species of the acid.

Claim 86 (new): The formulation of claim 84 which does not comprise anhydride species of the acid.

Claim 87 (new): The formulation of claim 24 wherein the formulation has an observed stoichiometry which would be consistent with the first species being boronate ions carrying a single negative charge.

Claim 88 (new): The formulation of claim 24 wherein the second species is selected from pharmaceutically acceptable metal ions, said metal ions having a valency of n, lysine, arginine or aminosugars, wherein the formulation has an observed stoichiometry of first to second species essentially consistent with a notional stoichiometry of 1:1 when the second species is a metal ion with a valency of 1 or is lysine, arginine or an aminosugar, or an observed stoichiometry of n:1 when the second species is a metal ion with a valency of greater than 1.

Claim 89 (new): The formulation of claim 24 wherein the boronic acid is of formula (VIII):

X-(R)-Phe-(S)-Pro-(R)-boroMpg-OH (VIII),

wherein X is R^6-$(CH_2)_p$-C(O)-, R^6-$(CH_2)_p$-S(O)$_2$-, R^6-$(CH_2)_p$-NH-C(O)- or R^6-$(CH_2)_p$-O-C(O)- wherein p is 0, 1, 2, 3, 4, 5 or 6 and R^6 is H or a 5 to 13-membered cyclic group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen; amino; nitro; hydroxy; a C_5-C_6 cyclic group; C_1-C_4 alkyl and C_1-C_4 alkyl containing, or linked to the cyclic group through, an in-chain O atom, the aforesaid alkyl groups optionally being substituted by a substituent selected from halogen, amino, nitro, hydroxy and a C_5-C_6 cyclic group; and boroMpg-OH is a residue of an aminoboronic acid of the formula H_2N-CH($(CH_2)_3$OMe)B(OH)$_2$.

Claim 90 (new): The formulation of claim 88 wherein X is R^6-$(CH_2)_p$-O-C(O)-.

Claim 91 (new): The formulation of claim 89 wherein R^6-$(CH_2)_p$-O-C(O)- and R^6 is a 6-membered cyclic group that is unsubstituted and p is 1.

Claim 92 (new): The formulation of claim 91 wherein the formulation has an observed stoichiometry which would be consistent with the first species being boronate ions carrying a single negative charge.

Claim 93 (new): The formulation of claim 24 wherein the boronic acid is of formula Cbz-(R)-Phe-(S)-Pro-(R)-boroMpg-OH and the second species comprises sodium ions, boroMpg-OH being a residue of an aminoboronic acid of the formula H_2N-CH($(CH_2)_3$OMe)B$(OH)_2$.

Claim 94 (new): The formulation of claim 93 which is a solution.

Claim 95 (new): The formulation of claim 24 wherein the formulation has an observed stoichiometry which would be consistent with the first species being boronate ions carrying a single negative charge, the boronic acid is of formula Cbz-(R)-Phe-(S)-Pro-(R)-boroMpg-OH, and the second species consists essentially of sodium ions, boroMpg-OH being a residue of an aminoboronic acid of the formula H_2N-CH($(CH_2)_3$OMe)B$(OH)_2$.

Claim 96 (new): The formulation of claim 24 wherein the boronic acid is of formula Cbz-(R)-Phe-(S)-Pro-(R)-boroMpg-OH and the second species comprises calcium ions.

Claim 97 (new): The formulation of claim 24 wherein the formulation has an observed stoichiometry which would be consistent with the first species being boronate ions carrying a single negative charge, the boronic acid is of formula Cbz-(R)-Phe-(S)-Pro-(R)-boroMpg-OH, and the second species consists essentially of calcium ions, boroMpg-OH being a residue of an aminoboronic acid of the formula H_2N-CH($(CH_2)_3$OMe)B$(OH)_2$.

Claim 98 (new): The formulation of claim 24, wherein:

the formulation is a solution,

Y comprises a dipeptide which binds to the S3 and S2 binding sites of thrombin, the S3-binding amino acid residue being of (R)-configuration and the S2-binding residue of (S)-configuration,

the fragment –NHCH(R^9)-B(OH) is of (R)-configuration, and

R^9 is methoxypropyl.

Claim 99 (new): The formulation of claim 98 wherein the formulation has an observed stoichiometry which would be consistent with the first species being boronate ions carrying a single negative charge.

Claim 100 (new): The formulation of claim 24 which is a solution, and wherein the formulation has an observed stoichiometry which would be consistent with the first species being boronate ions carrying a single negative charge, the boronic acid is of formula (VIII):

X-(R)-Phe-(S)-Pro-(R)- Mpg-B(OH)2 (VIII),

wherein R^6-$(CH_2)_p$-O-C(O)- and R^6 is a 6-membered cyclic group that is unsubstituted and p is 1,

and the second species is selected from magnesium, calcium and sodium ions.

Claim 101 (new): The formulation of claim 24, wherein:

the formulation is a solid dosage form,

Y comprises a dipeptide which binds to the S3 and S2 binding sites of thrombin, the S3-binding amino acid residue being of (R)-configuration and the S2-binding residue of (S)-configuration,

the fragment –NHCH(R^9)-B(OH) is of (R)-configuration, and

R^9 is methoxypropyl.

Claim 102 (new): The formulation of claim 101 wherein the formulation has an observed stoichiometry which would be consistent with the first species being boronate ions carrying a single negative charge.

Claim 103 (new): The formulation of claim 24 which is a solid dosage form, and wherein the formulation has an observed stoichiometry which would be consistent with the first species being boronate ions carrying a single negative charge, the boronic acid is of formula (VIII):

X-(R)-Phe-(S)-Pro-(R)-boroMpg-OH (VIII),

wherein R^6-$(CH_2)_p$-O-C(O)- and R^6 is a 6-membered cyclic group that is unsubstituted and p is 1,

and the second species is selected from magnesium, calcium and sodium ions.

Claim 104 (new): The formulation of claim 91 wherein the salt is an L-arginine salt or an L-lysine salt.

Claim 105 (new): The formulation of claim 91 wherein the salt is a sodium salt.

Claim 106 (new): The formulation of claim 91 wherein the salt is a lithium salt.

Claim 107 (new): The formulation of claim 91 wherein the salt is a glucamine salt.

Claim 108 (new): The formulation of claim 91 wherein the salt is a calcium or magnesium salt.

Claim 109 (new): The formulation of claim 91 which is adapted for intravenous administration, whether directly or after combining with a liquid, wherein the salt is a salt of the boronic acid with an aminosugar, a guanidine or an amine of formula (XI):



(XI)

where n is from 1 to 6, R^2 is H, carboxylate or derivatised carboxylate, R^3 is H, C_1-C_4 alkyl or a residue of a natural or unnatural amino acid.

Claim 110 (new): The formulation of claim 67 further comprising at least one further pharmaceutically active agent.

Claim 111 (new): The formulation of claim 110 wherein the further pharmaceutically active agent comprises a cardiovascular treatment agent selected from the group consisting of lipid-lowering drugs, fibrates, niacin, statins, CETP inhibitors, bile acid sequestrants, anti-oxidants, IIb/IIIa antagonists, aldosterone inhibitors, A2 antagonists, A3 agonists, a beta-blockers, acetylsalicylic acid, loop diuretics, ACE inhibitors, antithrombotic agents with a different mechanism of action, antiplatelet agents, thromboxane receptor and/or synthetase inhibitors, fibrinogen receptor antagonists, prostacyclin mimetics, phosphodiesterase inhibitors, ADP-receptor (P_2T) antagonists, thrombolytics, cardioprotectants and COX-2 inhibitors, and combinations thereof.

Claim 112 (new): The method of claim 25 wherein the formulation comprises an aqueous solution of a sodium salt of a boronic acid of the formula Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-$B(OH)_2$.

Claim 113 (new): The method of claim 25 wherein the sodium salt is the monosodium salt.

Claim 114 (new): The formulation of claim 24 which comprises a mixture of said second species, and wherein

Y comprises a dipeptide which binds to the S3 and S2 binding sites of thrombin, the S3-binding amino acid residue being of (R)-configuration and the S2-binding residue of (S)-configuration,

the fragment –NHCH(R^9)-B(OH) is of (R)-configuration, and

R^9 is methoxypropyl.

Claim 115 (new): The formulation of claim 1 wherein the organoboronic acid is of the formula Cbz-(R)-Phe-(S)-Pro-(R)-boroMpg-OH, wherein boroMpg-OH is a residue of an aminoboronic acid of the formula H_2N-CH((CH_2)$_3$OMe)B(OH)$_2$, the formulation comprising

a) a first species selected from said boronic acid, said boronic acid when in the form of boronate ions of said boronic acid, or equilibrium forms of said boronic acid and said boronate ions, or combinations thereof; and

(b) one or a mixture of pharmaceutically acceptable cations.

Claim 116 (new): A method for inhibiting thrombin in the treatment or prevention of disease in a subject, comprising parenterally administering to the subject a pharmaceutical formulation adapted to result, after administration of the formulation, in the release of boronate species obtainable from a boronic acid as defined in claim 1 and pharmaceutically acceptable cations.